

## Corrigendum

# Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial

Wolfgang Gaebel, Andreas Schreiner, Paul Bergmans, Rosario de Arce, Frédéric Rouillon, Joachim Cordes, Lars Eriksson and Enrico Smeraldi

*Neuropsychopharmacology* (2011) **36**, 548; doi:10.1038/npp.2010.206; published online 17 November 2010

**Correction to:** *Neuropsychopharmacology* (2010) **35**, 2367–2377; doi:10.1038/npp.2010.111; published online 4 August 2010

In this article, the authors would like to apologize for an error inadvertently introduced into the paper. During pre-marketing clinical studies, reactions that presented with signs and symptoms consistent with olanzapine overdose were reported in patients following an injection of olanzapine pamoate. These reactions occurred in <0.1% of the injections and in approximately 2% of patients, according to the EU SPC, for olanzapine pamoate.<sup>1,2</sup> In the EU SPC, at the moment the manuscript was written, post-injection delirium syndrome (PDSS) occurred in approximately 1% of patients. In the introduction section on page 2, we inadvertently stated that PDSS occurred after about 1% of olanzapine pamoate injections (Citrome, 2009). The authors intended to state that PDSS occurs in about

1% of patients receiving olanzapine pamoate injections. We now have updated the note according to the EU SPC, stating that PDSS occurs in <0.1% of olanzapine pamoate injections and in about 2% of patients.

<sup>1</sup>[http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000890/human\\_med\\_001188.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true](http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000890/human_med_001188.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124&jsenabled=true)

<sup>2</sup>[http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Product\\_Information/human/000890/WC500054429.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000890/WC500054429.pdf)

Citrome L (2009). Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic. *Int J Clin Pract* **63**: 140–150.